Dynavax Technologies

Dynavax Technologies Corp. operates as a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Emeryville, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Dynavax Technologies reports strong Q4 earnings, eyes continued growth

Dynavax Technologies showcased robust financial performance, driven by the success of HEPLISAV-B and CpG 1018 adjuvant. Progress in clinical development and market share growth were notable achievements. Challenges include maintaining market growth amidst competition and regulatory changes, while opportunities exist in expanding product revenue and advancing vaccine programs.

Dynavax reports record revenue growth, eyes market expansion opportunities

Dynavax Technologies showcased robust performance in Q1 2023, driven by record revenue growth and strong financial results.
While facing challenges such as uncertainties and competition, the company's strategic strengths and opportunities position it for continued success.
Management's focus on innovation, market expansion, and financial stability bodes well for future growth and shareholder value.
Overall, Dynavax Technologies remains optimistic about its outlook, supported by a dedicated team and a solid commercialization strategy.

Dynavax reports strong Q2 earnings, eyes growth through innovation

Dynavax Technologies delivered robust financial results in Q2 2023, driven by strong HEPLISAV-B revenue growth and increased market share.
The company's focus on innovation, market expansion, and financial stability positions it well for future growth and strategic opportunities.
While facing challenges in revenue sustainability and competition, Dynavax's strengths in market penetration and product pipeline offer avenues for continued success.
By leveraging opportunities in market expansion, product diversification, and strategic partnerships, Dynavax can further solidify its position in the vaccine and infectious disease spaces.

Dynavax reports record revenue growth and raises full-year guidance

Dynavax Technologies delivered a strong performance in Q3 2023, driven by record HEPLISAV-B revenue and market share gains.
While facing margin pressures from increasing expenses, the company's strategic focus on diversification and innovation bodes well for future growth.
With raised revenue guidance, a robust clinical pipeline, and a solid financial position, Dynavax is poised for continued success and market expansion.

Dynavax Technologies reports record revenue growth and strategic investments

Dynavax Technologies' Q4 2023 earnings call highlighted robust revenue growth, market leadership, and strategic investments in HEPLISAV-B.
The company's financial outlook for 2024, including revenue guidance and expense projections, reflects a balanced approach to growth and profitability.
With a strong cash position, ongoing pipeline developments, and focus on cost management, Dynavax is poised for continued success and market expansion.

Dynavax Technologies reports robust Q1 earnings and growth outlook

Dynavax Technologies delivered solid financial results in Q1 2024, driven by continued growth in HEPLISAV-B net product revenue and a focus on innovation and R&D advancement.
Despite market challenges and expenses, the company's strong cash position, market leadership, and upcoming milestones position it well for sustainable growth and success.
With a clear strategic focus on driving growth, maintaining market share, and advancing its vaccine portfolio, Dynavax is poised for a promising future in the healthcare industry.

Dynavax reports record sales and market share gains in Q2 2024

Dynavax Technologies delivered strong financial performance in Q2 2024, driven by record HEPLISAV-B sales and market share gains.
The company's pipeline progress and robust cash position position it well for future growth and innovation.
While challenges in managing expenses persist, strategic opportunities and a positive outlook for HEPLISAV-B offer avenues for sustained success.
Dynavax's focus on cost management, market expansion, and product development will be key to capitalizing on opportunities and overcoming challenges.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Medigen Vaccine Biologics Corporation and Dynavax Technologies Corporation (NASDAQ: DVAX) announced the rollout of their COVID-19 vaccine, MVC-COV1901, in Taiwan.  Approximately 600,000 people are anticipated to receive the Medigen vaccine this week.

Powered By Dynavax Adjuvant, Medigen COVID-19 Vaccine Launched In Taiwan

TAIPEI, Taiwan and EMERYVILLE, Calif., Aug. 23, 2021 /PRNewswire/ -- Medigen Vaccine Biologics Corporation (MVC) (TPEx: 6547.TWO), a biopharmaceutical company focusing on the development and production of vaccines and biologics, and Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced the rollout of its COVID-19 vaccine, MVC-COV1901.

Medigen Vaccine Biologics Announces Launch of Its COVID-19 Vaccine MVC-COV1901 Adjuvanted with Dynavax's CpG 1018 Adjuvant

Inovio Pharmaceuticals

Novavax

Investors appeared to be rattled by the U.S. government's decision to move forward with booster doses of mRNA vaccines.

Why Dynavax, Novavax, and Inovio Stocks Sank This Week

Sorrento Therapeutics Inc

There were different reasons behind each of these COVID-19 vaccine stocks' big gains.

Why Dynavax, Novavax, and Sorrento Soared This Week

GT Biopharma Inc

iShares Nasdaq Biotechnology ETF

Health Care Select Sector SPDR Fund

Merck's FDA and coronavirus vaccine news sparked momentum in biotech stocks today. Here are 4 to watch.

Former Penny Stocks To Watch After Merck's (MRK) Latest FDA Win

Agenus

Is it time to add biotech stocks to your list this year? The post Hot Biotech Stocks That Deserve Your Attention In August 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Hot Biotech Stocks That Deserve Your Attention In August 2021

BioNTech SE

Moderna

Each vaccine stock had its own separate catalyst.

Why COVID Vaccine Stocks Moderna, BioNTech, Novavax, and Dynavax Soared This Week

Pacific Biosciences of California

Cassava Sciences Inc

Have penny stocks presented some of the biggest opportunities in the stock market? The post Are Penny Stocks Worth It?

Are Penny Stocks Worth It? 5 That Deserve Your Attention Now

Dynavax Technologies Corporation (DVAX) CEO Ryan Spencer on Q2 2021 Results - Earnings Call Transcript

Dynavax Technologies (DVAX) delivered earnings and revenue surprises of 150.00% and 19.82%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Dynavax Technologies (DVAX) Q2 Earnings and Revenues Top Estimates

EMERYVILLE, Calif., Aug. 4, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for the second quarter of 2021.

Dynavax Announces Second Quarter 2021 Financial Results

Dynavax earned $83.3m in Q121 - up >650% year-on-year. The uplift was largely due to its vaccine adjuvant, CPG-1018, which is being used by multiple COVID vaccine developers.

Dynavax: Earnings This Year Ought To Surprise To The Upside

Dynavax Technologies (DVAX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Dynavax Technologies (DVAX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

EMERYVILLE, Calif. , July 21, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, will report second quarter 2021 financial results on Wednesday, August 4, 2021, after the U.S. financial markets close.

Dynavax to Report Second Quarter 2021 Financial Results and Host Conference Call on August 4, 2021

EMERYVILLE, Calif. and HYDERABAD, India, July 6, 2021 /PRNewswire/ --  Dynavax Technologies Corporation (Dynavax, Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines and Biological E.

Dynavax and Biological E Announce Commercial Supply Agreement of Dynavax's CpG 1018 Adjuvant for Biological E's COVID-19 Vaccine Candidate

The company inked a significant supply deal for its vaccine adjuvant.

Why Dynavax Stock Has Jumped 11% So Far This Week

Clover Biopharmaceuticals and Dynavax Technologies Corporation (NASDAQ: DVAX) have executed the commercial supply agreement of Dynavax's CpG 1018TM advanced adjuvant for use in Clover's protein-based COVID-19 vaccine candidate, SCB-2019 (CpG 1018/Alum).  The commercial supply agreement extends to the end of 2022.

Clover, Dynavax Ink Commercial Supply Agreement For CpG 1018 Adjuvant

Clover to procure CpG 1018 adjuvant from Dynavax for use in the commercial production of Clover's COVID-19 vaccine candidate, SCB-2019 (CpG 1018/Alum) Pending conditional regulatory approvals, Clover expects to commence product launch of SCB-2019 (CpG 1018/Alum) by the end of 2021 CHENGDU, China and EMERYVILLE, Calif., June 30, 2021 /PRNewswire/ -- Clover Biopharmaceuticals (Clover), a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates to address the world's most life-threatening diseases and public health threats, and Dynavax Technologies Corporation (Dynavax, Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced the execution of a commercial supply agreement of Dynavax's CpG 1018TM advanced adjuvant, for use in Clover's protein-based COVID-19 vaccine candidate, SCB-2019 (CpG 1018/Alum).

Clover and Dynavax Announce Commercial Supply Agreement of Dynavax's CpG 1018 Adjuvant for Clover's COVID-19 Vaccine Candidate

EMERYVILLE, Calif., June 29, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) today announced that, in connection with the appointment of John Slebir as Senior Vice President, General Counsel on June 28, 2021, the Company granted him a non-statutory stock option to purchase 300,000 shares of Dynavax common stock.

Dynavax Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Vaxart

The declines appear to be caused simply by volatility that's common with small biotech stocks.

Why COVID Vaccine Stocks Dynavax, Novavax, and Vaxart Are Sinking Today

EMERYVILLE, Calif., June 9, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that Ryan Spencer , Chief Executive Officer, will present virtually at the Goldman Sachs 42nd Annual Global Healthcare Conference on Thursday, June 10, 2021 at 3:50 p.m.

Dynavax to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference

Saint- Herb lain (France ) , June 3 , 2021 –Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, today announced that it has completed recruitment for the pivotal Phase 3 trial of its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001.

Valneva Completes Phase 3 Trial Recruitment for its Inactivated COVID-19 Vaccine Candidate

The company signed a key deal to market its hepatitis B vaccine in Germany.

Why Dynavax Stock Is Rising Today

Dynavax Technologies Corporation (NASDAQ: DVAX) has entered into a commercialization agreement with Bavarian Nordic for the marketing and distribution of HEPLISAV B, the Hepatitis B vaccine in Germany, with an expected launch in the fourth quarter of 2021. Financial terms were not disclosed.

Dynavax, Bavarian Nordic Ink Distribution Pact For Hepatitis B Vaccine In Germany

EMERYVILLE, Calif., May 27, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced it has entered into a commercialization agreement with Bavarian Nordic for the marketing and distribution of HEPLISAV B [Hepatitis B Vaccine (Recombinant), Adjuvanted] in Germany with an expected launch in the fourth quarter of 2021.

News for Dynavax Technologies Stock (DVAX)